TickerTalks
Browse all tickers →
TickerTalks›$PTGX
PTPTGX

Protagonist Therapeutics, Inc.

$PTGX·$8.3B·Biotechnology·Healthcare
$128.75-5.7%YTD+60.0%1Y+70.0%
Price updated 8h ago·X counts updated 5d ago
PTPTGX
$PTGXProtagonist Therapeutics, Inc.
$128.75-5.71%47 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PTGX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

47X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $PTGX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data10 posts analyzed · as of 2026-09-15

Protagonist announces a $300M share buyback (against only 64.7M shares outstanding) funded by cash plus Takeda/JNJ royalty streams, framing a position of strength. Bulls flag a $55B+ oral IL-17 opportunity and treat the buyback as a decisive capital-return signal.

Read what X is saying about $PTGX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PTGX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Protagonist up 62% YTD on IL-17 narrative and a $300M buyback — but the CEO and COO took home $17M at $146 in one week.

Protagonist Therapeutics has become the oral IL-17 pure play of the moment — a $9B market cap, a $300M buyback funded by Takeda and JNJ royalty streams, and the Q2 revenue of $213M beat consensus by 7.5% on the back of ruzasvir and prior-year milestones.

  • The sell-side revenue line jumps from $4.7M in Q3 2025 to $213M in Q2 2026, with 2026 EPS at $4.67 falling to -$0.49 in 2027 before recovering to $1.96 in 2028 and $4.29 in 2029 — milestone-driven, not run-rate.
  • The $300M buyback against only ~65M shares outstanding is meaningful, but CEO Patel sold $9.3M of stock at $146 on September 9 (plus another $1.05M the next day) and COO Ali sold $8.3M at $141.78 on September 30 — the open-market sales total ~$18M in three weeks.
  • The $55B+ oral IL-17 opportunity is the structural catalyst, with the broader obesity/immunology peptide pipeline providing optionality — but the forward multiple at $9B is pricing in near-perfect pipeline execution for the next 24 months.

At $140 and 79% of the 52-week range, the stock has already captured the first ruzasvir and buyback catalysts; the November 5 Q3 earnings and clinical commentary on the oral IL-17 asset is the next test, with the recent insider sales setting a near-term ceiling until proven otherwise.

Agrees with X sentimentX is bullish framing the $300M buyback as capital-return conviction and the IL-17 opportunity at $55B+; the TickerTalks read agrees on the structural thesis but weighs the $18M of insider sales in three weeks as a near-term tactical ceiling.

What to watch: November 5 Q3 earnings and oral IL-17 clinical readout updates; buyback execution pace and any additional milestone-driven revenue recognition; follow-on insider activity after Patel and Ali's $18M of September-October sales.

On the calendar: Q3 earnings scheduled 2026-11-05

Read the AI verdict on $PTGX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops peptide-based drugs for blood disorders, with rusfertide in late-stage trials for polycythemia vera.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PTGX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $PTGX

Neutral — Develops peptide-based drugs for blood disorders, with rusfertide in late-stage trials for polycythemia vera.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-55.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-21.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-192%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
84.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-17.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$2.29$2.23+2.7%
Q1 2026May 5, 2026$0.05$-0.65+107.7%
Q4 2025Feb 25, 2026$-0.69$-0.53-30.2%
Q3 2025Nov 6, 2025$-0.62$-0.59-5.1%
Next earningsThu, Nov 5·consensus EPS $2.39

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$56.4M+99.0%99.3%-6.5%$0.06$-49.2M
Q4 FY25$7.4M-95.6%100%-677%$-0.69$-35.5M
Q3 FY25$4.7M+0.8%100%-985%$-0.62$-2.0M
Q2 FY25$5.5M+33.1%100%-758%$-0.55$-29.6M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$543.4M$521.9M – $574.9M$4.67$3.93 – $5.949
FY27$192.7M$97.5M – $284.9M-$0.49-$19.63 – $33.309
FY28$378.1M$103.2M – $831.6M$1.96-$2.73 – $7.419
FY29$588.5M$391.6M – $908.0M$4.29$2.42 – $7.314
FY30$835.5M$556.1M – $1.3B$7.26$4.11 – $12.394

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.63%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-11.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 52.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.795-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 30Asif AliCFO58.6K sh$8.3MSellSep 10Dinesh V PatelCEO7.3K sh$1.0MSellSep 9Dinesh V PatelCEO63.5K sh$9.3MSellSep 8Dinesh V PatelCEO54.2K sh$7.9MSellAug 11Dinesh V PatelCEO34.2K sh$5.1MSellAug 10Dinesh V PatelCEO65.8K sh$9.8MSellJun 23William D. WaddillDirector9.0K sh$1.1MSellJun 10William D. WaddillDirector9.0K sh$969KSellMay 29William D. WaddillDirector9.0K sh$897KSellMay 12Dinesh V PatelCEO75.0K sh$7.5M
1–10 of 13
+ 13 other (11 exempts · 2 gifts) in window

See when $PTGX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PTGX filed an 8-K (Item 2.02) reporting its financial results for the Second Quarter 2026 Financial Results and Provides Corporate Update” is furnishe, filed 2026-08-05. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Protagonist Therapeutics' 2026 Annual Meeting on June 17, 2026 approved the 2026 Equity Incentive Plan replacing the 2016 plan, adding 650,000 new shares plus any shares recycled from expired/forfeited awards under the old plan. The new plan supports grants of stock options (incentive and non-qualified), SARs, restricted stock/RSUs, and other stock-based awards. Routine annual meeting governance also included director elections and other standard proposals. Mildly dilutive — the 650K net new share addition is modest; the recycled-award feature limits incremental dilution beyond what was already authorized.

+ 23 other (11 S-8 POSs · 5 13Gs · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)defenseworld.net·1d agoProtagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Knowzacks.com·2d agoProtagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Reviewdefenseworld.net·23d agoProtagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stockdefenseworld.net·34d agoProtagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stockdefenseworld.net·34d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $PTGX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport